Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky Sells 187,655 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 187,655 shares of Tempus AI stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. This represents a 1.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempus AI Trading Up 7.6 %

Shares of TEM opened at $35.54 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The company has a 50 day simple moving average of $51.44. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $79.49.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently modified their holdings of the business. Kovitz Investment Group Partners LLC bought a new stake in Tempus AI in the 3rd quarter valued at approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $2,726,000. Sigma Planning Corp bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $1,323,000. Finally, Dakota Wealth Management bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $1,185,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research reports. Bank of America lifted their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.